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Are nutritional status indicators associated with mortality in the
Hemodialysis (HEMO) Study?
Background. The purpose of this study was to determine if
indicators of nutritional status were associated with subsequent
mortality in hemodialysis patients.
Methods. Twelve selected nutrition indicators were mea-
sured prior to randomization in the Mortality and Morbidity
in Hemodialysis (HEMO) Study. Relative risks (RR) of mor-
tality were assessed at <6 months and >6 months of follow-up
using Cox regression after controlling for case mix, comorbid-
ity, and treatment assignment (high vs. standard Kt/V and high
vs. low membrane flux).
Results. Low values of most nutritional status indicators were
associated with increased RR of mortality. RRs were greatest
over the short term (<6 months) and diminished with increasing
follow-up (>6 months). Increases in body mass index (BMI) at
lower levels (e.g., ≤25 kg/m2) and increases in serum albumin
at any level were associated with reduced short-term RR, even
after adjusting for case mix, treatment assignment, and for the
joint effects of equilibrated normalized protein catabolic rate,
total cholesterol, and serum creatinine. For >6 months’ follow-
up, increases in values among those with lower levels of BMI
and serum albumin (≤3.635 g/dL) and increases in all serum
creatinine levels were associated with lower RR.
Conclusion. Nutrition indicators are associated with subse-
quent mortality in a time-dependent manner, with greatest ef-
fects at <6 months of follow-up. The RR for these indicators
may also vary within different ranges of values.
Key words: nutrition, serum albumin, BMI, body weight, hemodialysis,
anthropometry.
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Depending on the nutritional assessment method used,
malnutrition is evident in 18% to 75% of persons on main-
tenance hemodialysis, and its presence often presages
subsequent mortality [1–6]. Identification of those base-
line nutritional indicators related to mortality during dif-
ferent periods of follow-up would allow early, focused
prognosis and timely clinical intervention. However, only
a few studies of hemodialysis and malnutrition have in-
corporated detailed data on comorbidity or dialysis dose.
The goals of the present analyses were to determine if
baseline nutritional status parameters were independent
factors associated with mortality during follow-up peri-
ods of <6, 6–18, and >18 months among subjects in the
National Institutes of Health (NIH)-sponsored Mortality
and Morbidity in Hemodialysis (HEMO) Study. We also
investigated whether the relative risks of mortality asso-
ciated with baseline nutritional parameters were linear,
as many previous analyses have assumed.
METHODS
Design and HEMO Study subjects
The HEMO Study was a prospective, multicenter ran-
domized clinical trial sponsored by the National Institute
of Diabetes, Digestive and Kidney Disease (NIDDK) of
the NIH that compared the effects of high versus standard
dose (eKt/V urea) and high versus low flux membranes
in a 2 × 2 factorial design on morbidity and mortality in
hemodialysis patients [7, 8]. The sample of 1846 subjects
between 18 and 80 years old was randomized between
March 1995 and October 2000. All subjects were under-
going thrice weekly, in-center hemodialysis for at least
3 months at study entry. Subjects were excluded if their
serum albumin was <2.6 g/dL by nephelometry, if they
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failed to achieve an eKt/Vurea of >1.30 within 4.5 hours
for 2 of 3 consecutive monitored dialyses targeting the
high dose dialysis goal, if serious comorbid medical con-
ditions were present, or if their residual urea clearance
exceeded 1.5 mL/min per 35 L of urea volume [7]. The In-
stitutional Review Boards at the 15 institutions approved
the study protocol and written informed consent was ob-
tained from all study participants.
Nutritional and dietary factors and comorbidity
Nutrition was not a HEMO study intervention, but 12
nutritional status indicators were assessed at baseline and
during follow-up to monitor nutritional status. Details on
the baseline nutritional status of the HEMO study cohort
are available [9]. To better differentiate various aspects
of nutritional status we examined biochemical, anthro-
pometric, and dietary indicators collected routinely in
clinical situations. Measures taken while subjects were
still receiving their prerandomization dialysis prescrip-
tions were included in our analyses [8].
Biochemical indicators included serum albumin
measured at a central laboratory by nephelometry,
equilibrated normalized protein catabolic rate (enPCR)
calculated from formal urea kinetic models using both
single and double pool Kt/Vurea, and also serum creati-
nine and total serum cholesterol (t-chol) assessed locally
at each clinical center laboratory [10].
Anthropometric indicators included postdialysis
weight, which was measured monthly. BMI was calcu-
lated from postdialysis weight and stature, with stature
measured directly or, in the case of amputees or those
unable to stand, estimated from knee height using the
formula of Chumlea et al [11]. The estimated total
body water volume (Watson V), also referred to as
anthropometric volume, was calculated from postdialysis
weight, height, age, and using the sex-specific Watson
formula [12]. Other anthropometric measures were
collected using previously published methods [13, 14].
Calf circumference (CC) and mid-arm circumference
(MAC) served as proxies for lean body mass; and
subscapular skinfolds (SS) indirectly estimated the level
of body fatness.
The dietary indicators, dietary energy intake (DEI),
and dietary protein intake (DPI) were assessed from 2-
day diet diary-assisted recalls. Details of the methods for
collecting and calculating these measures have been pre-
viously described [15].
Case-mix and comorbidity indicators
Case-mix characteristics were represented by age, sex,
years on dialysis (which was modeled allowing separate
linear associations for values above and below the 10
year point), presence of diabetes, and African Ameri-
can versus non-African American race. To account for
the level of comorbidity, 9 baseline comorbidity in-
dicators were collected, including 8 individual disease
severity scores (congestive heart failure, arrhythmias and
conduction problems, cerebral vascular disease, other
heart disease omitting peripheral heart disease, respi-
ratory disease, nonvascular nervous system disease, gas-
trointestinal disease, and malignancy). We also examined
results from the Karnofsky Index, an objective observer’s
clinical evaluation of physical functioning on a 10-point
scale [16].
Statistical analysis
Continuous variables were described as means and
standard deviations while categorical variables were de-
scribed as frequencies and percentages. The relative
volatility of the different nutrition measures, which quan-
tified the degree to which within-patient marker val-
ues fluctuated with time, was quantified by computing
changes from baseline to the first year of follow-up and
then creating a ratio of the standard errors within sub-
jects divided by the standard errors of the changes among
subjects.
Proportional hazards (Cox) regression was used to ex-
amine effects of baseline nutritional status markers on
survival [17, 18]. Results were reported as relative risks
(RR) with 95% confidence limits (95% CI) and expressed
in units of change deemed to be clinically meaningful by
the HEMO nutrition group. All models controlled for
case-mix and treatment assignment and were stratified
by clinical center. We censored subjects for transplanta-
tion (N = 194) and transfer to nonparticipating facilities
or change of dialysis modality (N = 198).
Preliminary analyses determined whether changes in
RR associated with incremental differences in the nutri-
tional status parameters varied depending on their mag-
nitude. Possible nonlinear effects were modeled using
restricted cubic splines, and where nonlinear RR signif-
icantly improved model fit, associations were approxi-
mated using separate linear slopes for values above and
below the median [19]. Otherwise, the associations were
modeled using single linear slopes so that RR for incre-
mental differences remained uniform regardless of the
value range. Sex differences were explored for the 2-
slope cut-points and the RR for each modeled slope.
Each nutritional status indicator was tested individually
in this way. These are henceforth referred to as univariate
models.
We tested for prespecified multiplicative effects that
the HEMO nutrition group considered biologically plau-
sible. The pairwise interactions included: serum albumin
with age; serum creatinine with age; serum albumin with
sex, BMI with sex; serum creatinine with black race;
serum albumin with presence of diabetes; serum albumin
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with years on dialysis; and serum creatinine with years on
dialysis.
Baseline nutritional status effects were tested over the
follow-up periods <6 months, 6 to 18 months, and >18
months in the univariate models described above to ascer-
tain whether short- and long-term effects differed. Time
dependencies were tested using time-by-nutrition value
interactions. Resulting relationships were generally non-
linear with time-dependency largely falling off after the
first 6 months. Differences between the RR for <6 follow-
up months and ≥6 months were tested and described as
a ratio (RR for the first 6 months/RR for the subsequent
period; inverted if >1).
To identify nutritional markers independently asso-
ciated with mortality, the effects of t-chol, serum cre-
atinine, serum albumin, BMI, and enPCR were jointly
modeled while controlling for case-mix and treatment
assignment. We initially examined the degree of mul-
ticollinearity among these variables by inspecting the
x-matrix eigenvalues, condition indices, and the decom-
position of the variances of the estimates with respect
to each eigenvalue in a matrix format using the method
of Belsey et al [20]. Then the independent effects were
tested in separate multivariate models relating to the first
6 months of follow-up and to the period thereafter.
To determine the extent of confounding by comorbid-
ity, we added a set of independently associated comorbid
factors to the existing case-mix and treatment assignment
controls. We then noted changes in the RRs for the differ-
ent levels of each nutritional status index produced by the
augmented univariate, time-dependent, and multivariate
models.
Two-tailed P values below 0.05 were considered signif-
icant. Given the exploratory nature of these analyses, we
did not adjust for multiple comparisons. Statistical analy-
ses were conducted using SAS 8.0 (Cary, NC, USA) and
S-Plus 6.0 (Redmond, WA, USA).
RESULTS
Subject characteristics
The mean age of the HEMO Study subjects was 57.6
years; 56.2% were female, and 62.6% African American.
Follow-up time for the HEMO cohort ranged from a few
days to 5.6 years. Death and transplant-related attrition
resulted in a mean follow-up time of 2.84 years. Table 1
presents the nutritional status characteristics of subjects
with the relative degree of volatility of the measures.
Because there were no significant effects of the random-
ized interventions, all subjects were pooled for descriptive
purposes.
Mean biochemical and anthropometric nutritional pa-
rameters fell within the normal range for the general pop-
ulation, but the distributions were highly variable with
many subjects having abnormal values for at least 1 mea-
Table 1. Baseline characteristics of the Hemodialysis (HEMO) Study
population and relative fluctuation of nutritional measures over time
Volatility index:
Within patient
SE/Between
Factors N Mean ± SD patient SEa
Biochemical indices
Nephelometry albumin g/dL 1846 3.62 ± 0.36 1.08
enPCR g/kg/day 1846 1.03 ± 0.24 1.12
Serum creatinine mg/dL 1845 10.3 ± 2.9 0.74
T-chol mg/dL 1672 173 ± 41 0.82
Anthropometric measures
Postdialysis weight kg 1846 69.2 ± 14.7 0.37
Watson volume L 1846 34.9 ± 6.1 0.25
BMI kg/m2 1800 25.5 ± 5.3 0.42
Calf circumference cm 1812 33.3 ± 4.0 0.61
Mid arm circumference cm 1841 30.1 ± 5.1 0.59
Subscapular skinfolds mm 1621 17.3 ± 8.3 0.62
Dietary intakes
Adj. energy intake kcal/kg/day 1844 22.7 ± 8.2 1.02
Adj. protein intake g/kg/day 1844 0.93 ± 0.35 1.19
Functional status
Karnofsky index 1845 80.6 ± 16.7 –
a Standard errors calculated from changes from baseline to follow-up year 1.
sure. Mean DPI and DEI values fell below the National
Kidney Foundation Disease Outcomes Quality Initiative
(NKF-K/DOQI) recommendations of 1.2 g/kg/d and 30
to 35 kcal/kg/d, respectively, for individuals with chronic
kidney disease (CKD) stage V [15, 21].
Serum albumin, enPCR, DEI, and DPI values exhib-
ited the highest volatility ratio, indicating that these mea-
sures varied more within subjects over time than between
subjects. In contrast, the volatility ratio was <0.5 for BMI,
postdialysis weight, and Watson V. Other indices fell be-
tween these 2 extremes.
The mean Karnofsky Index score was 80.6 ± 16.7 SD.
Comorbidities were common; nearly three quarters of the
patients had mild/moderate or severe ischemic and other
heart disease (73.3%), nearly half had gastrointestinal
and hepatobiliary disease (46.3%), approximately a third
exhibited congestive heart failure (39.7%) or arrhyth-
mias and conduction problems (31%). Moreover, 37.2%
exhibited mild/moderate or severe nonvascular nervous
system disease, 36.6% cerebral and peripheral vascular
disease, 15.4% respiratory disease, and 5.3% malignan-
cies.
Univariate associations among nutritional status
parameters and mortality
Table 2 shows the results of the Cox models for in-
dividual baseline nutrition markers after controlling for
case-mix and treatment assignment. The “attenuation of
relative risk statistics” of longer versus shorter follow-
up (the ratios of the <6 follow-up month RR over the
≥6 follow-up month RR) are also shown in Table 2.
Among the nutrition variables with RR modeled using
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Table 2. Relative risk of time to mortality models for baseline nutrition indicators
Relative risk per one increment
elevation in the baseline value Attenuation of relative
risks statistic:
Variable range Overall relative Longer vs. shorter
Variable (increment for relative risk) for effects risk (CI) P value follow-upa P value
Serum albumin per 0.25 g/dL ≤3.635 g/dL 0.72 (0.66–0.79) <0.0001 0.75 0.0080
>3.635 g/dL 0.90 (0.80–1.01) 0.077 0.65 0.12
enPCR per 0.25 g/kg/day ≤1.015 g/kg/d 0.79 (0.67–0.93) 0.0040 0.80 0.35
>1.015 g/kg/d 1.06 (0.91–1.22) 0.46 0.97 0.90
Serum creatinine per mg/dL All values 0.87 (0.84–0.90) <0.0001 1.0 0.92
t-chol per 10 mg/dL ≤168 mg/dL 0.93 (0.89–0.96) 0.0002 0.92 0.15
>169 mg/dL 0.99 (0.96–1.02) 0.52 –b –
DPI per 0.25 g/kg/day All values 1.14 (0.68–1.97) 0.63 –b –
DEI per 2.5 kcal/kg/day All values 1.03 (0.99–1.07) 0.095 0.99 0.90
BMI per kg/m2 ≤25 kg/m2 0.89 (0.86–0.92) <0.0001 0.85 0.0006
>25 kg/m2 0.99 (0.97–1.02) 0.58 –b –
Weight (women) per 2.5 kg ≤65.45 kg 0.94 (090–0.97) 0.0003 0.93 0.18
>65.45 kg 0.99 (0.96–1.02) 0.53 –b –
Weight (men) per 2.5 kg All values 1.00 (1.00–1.00) 0.45 0.99 0.21
Watson volume (women) per 2 L ≤30.97 L 0.81 (0.73–0.90) <0.0001 0.89 0.44
>30.97 L 0.99 (0.91–1.08) 0.80 –b –
Watson volume (men) per 2 L All values 1.00 (1.00–1.01) 0.22 0.99 0.31
SS per 5 mm ≤15.9 mm 0.83 (0.73–0.93) 0.0025 0.72 0.059
>15.9 mm 0.94 (0.87–1.01) 0.099 –b –
CC per 2 cm ≤33.25 cm 0.93 (0.88–0.97) 0.0030 0.87 0.062
>33.25 cm 0.90 (0.83–0.97) 0.0046 0.84 0.23
MAC (women) per 2 cm ≤34 cm 0.95 (0.93–0.97) <0.0001 0.95 0.071
>34 cm 0.98 (0.94–1.03) 0.47 –b –
MAC (men) per 2 cm ≤28 cm 0.88 (0.85–0.92) <0.0001 0.83 0.0010
>28 cm 1.00 (0.96–1.03) 0.90 –b –
All results adjusted for effects of HEMO dose and flux treatment assignment, age, sex, black race, presence of diabetes, and dialysis duration.
aRatio of the relative risks for the first 6 months of follow-up over the relative risks for the period after the first 6 months. The smaller this statistic, the greater the
attenuation between the two periods.
bAttenuation statistic not computed because relative risk changed from one direction during the first 6 months to another in the period thereafter.
a single slope, only serum creatinine was associated with
mortality risk (average mortality reduction of 13% for
1 mg/dL elevation in baseline value). Among the nutri-
tion variables modeled with 2 slopes (to better represent
the differing associations between the low and the high
value ranges), elevated levels within the range of values
up to the median were associated with mortality reduc-
tions for serum albumin (≤3.635 g/dL), total cholesterol
(≤168 mg/dL), enPCR (≤1.015 g/kg/d), women’s body
weight (≤65.45 kg), women’s Watson V (≤30.97 L), BMI
(≤25kg/m2), SS (≤15.9 mm), and MAC for both men
(≤28 cm) and women (≤34 cm). It should be noted that
subjects with serum albumin levels <2.6 g/dL were not
eligible for the study, and so results with serum albumin
only apply to subjects with levels above 2.6 g/dL.
Figures 1 through 7 provide illustrations of the effects
described above. The figures present the variable ranges
divided into the clinically distinguishable groups, as delin-
eated by the HEMO nutrition collaborators, and contrast
their RR to that of a group representing normative val-
ues. For example, Figure 1 illustrates that subjects with
low serum creatinine (those <12 mg/dL) had elevated
relative risks compared to a group defined as having nor-
mative serum creatinines of 12 mg/dL or greater. Figure 2
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Fig. 1. Serum creatinine: Relative risks (with 95% CI) for categories
of baseline values adjusting for baseline demographic variables.
shows that subjects with low serum albumin values (<3.6
g/dL) had elevated relative risks of mortality compared
to the reference (≥4.0 g/dL). Figure 3 shows that those
with total cholesterol value below 160 mg/dL also had
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Fig. 3. Total cholesterol: Relative risks (with 95% CI) for categories
of baseline values adjusting for baseline demographic variables.
elevated relative risks compared to patients with levels
between 180 and 200 mg/dL. Figure 4 shows that similar
effects were evident for low MAC values (categories be-
low 26 cm for both men and women) compared to the
reference of 26 to <32 cm for men and 26 to <34 cm
for women. Figure 5 shows similar effects for low CC
(<31 cm compared to a reference of 31 to <36 cm).
Figure 6 shows that while BMI values <19 kg/m2 were
associated with increased relative risk compared to the
reference of 22 to <25 kg/m2, categories >28 kg/m2 were
associated with decreased risk. Figure 7 shows a similar
pattern for SS values, with those below 7 mm showing
elevated risks and the group in the 24 to 31 mm range
showing decreased risks compared to the reference of 11
to <24 mm.
Women:
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Fig. 4. Arm circumference for men and women: Relative risks (with
95% CI) for categories of baseline values adjusting for baseline demo-
graphic variables.
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Fig. 5. Calf circumference: Relative risks (with 95% CI) for categories
of baseline values adjusting for baseline demographic variables.
None of the prespecified interactions examined were
significant in the presence of case-mix and treatment ef-
fects. Age and serum creatinine showed borderline signif-
icance with P = 0.064 (RR = 1.02 for each mg/dL increase
in serum creatinine per decade increase in age).
Time trends in relative risk
Time trends for the nutritional status indicators mod-
eled with a single slope are illustrated in Figure 8. Note
that serum creatinine exhibited a strong protective effect
that remained stable over follow-up, whereas the effects
for the other nutritional variables diminished over time
and became nonsignificant with follow-up greater than
18 months. The time trends associated with the lower
range of nutritional indicators using 2-slopes to model
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the parameters’ nonlinear associations are presented in
Figure 9. Protective effects were evident for increased
levels of several indicators, especially for serum albu-
min and BMI, and to a lesser extent, for enPCR, total
cholesterol, weight for women, Watson V for women, SS,
CC, and MAC for both men and women, at least during
the short term. These effects attenuated thereafter, al-
though serum albumin, t-chol, BMI, and MAC for men
remained protective for >18 months. Figure 10 shows that
among the effects associated with increases in the indica-
tors, among subjects having the higher ranges of values
at baseline, only women’s MAC for follow-up <6 months
and women’s SS during months 6 to 18 months were asso-
ciated with mortality (RR = 0.89 per 2 cm increase, 95%
CI 0.81 to 0.98 and RR = 0.89 per 2 cm increase, 95% CI
0.81–0.98, respectively).
To summarize how the effect of these baseline values
attenuated over time, using the attenuation statistic we
tested whether the RR for <6 months of follow-up,
whether protective or threatening, were significantly
stronger than those for the subsequent follow-up period.
The relative risks among those with lower levels of serum
albumin, BMI, and MAC for men diminished significantly
over time, suggesting that attenuation did occur.
Multivariate associations among select nutritional status
parameters and mortality
To determine which nutritional status markers were
independently associated with mortality in the HEMO
Study cohort, we simultaneously examined both short-
and long-term associations (<6 months, ≥6 months)
for serum creatinine, serum albumin, t-chol, BMI, and
enPCR after adjusting for case-mix and treatment as-
signment. Table 3 shows that for short-term follow-up
(<6 months), incremental increases in values among
those at both higher and lower levels of serum albumin
at baseline were associated with decreased risk of mor-
tality, as were increases among those who had lower BMI
values at baseline. For follow-up over the longer term
(≥6 months of follow-up), the adverse effects of lower
serum albumin and BMI persisted while those subjects
already at upper levels for serum albumin at baseline did
not experience adverse effects. Higher serum creatinine
was protective only over the longer term.
We also assessed whether the protective effects seen
among subjects with higher BMI could have been at-
tributed to increases in lean body mass by evaluating
regression models with and without serum creatinine
(the best available proxy for muscle mass). The risk ra-
tios associated with higher BMI were virtually identi-
cal [with creatinine: short-term RR = 0.83 (0.77−0.91),
long-term RR = 0.94 (0.90−0.98); without creatinine:
short-term RR = 0.83 (0.76−0.90), long-term RR = 0.93
(0.90−0.97)].
After adjusting for case-mix and treatment, we also
controlled for comorbid factors to determine whether the
associations of nutritional status parameters with mortal-
ity were heavily confounded by comorbidity. We found
that the univariate model RR changed very little after
adjusting for comorbidity, suggesting that the nutrition
parameters were independently associated with relative
risk of mortality. Indeed, RR changed by less than 1%
for over half [14] of the 25 tests of nutrition markers.
DISCUSSION
After previously finding that MAC and CC declined
over 3 years of follow-up in the high flux arm and that
enPCR was higher in the high dose arm [15], a careful
inquiry into nutritional status indicators in the HEMO
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Fig. 8. Relative risks (and 95% CIs) asso-
ciated with designated increases among all
values of certain baseline nutrition variables.
Relative risks shown by follow-up period: first
6 months (solid circles), 6 to 18 months (circles
with crosses), and subsequently (squares).
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Results were adjusted for dose and flux treatment group, age, gender (except for
women's weight and Watson V, and arm circ. and mne's arm circ.), black race, diabetic
status, and dialysis duration.
Fig. 9. Relative risks (and 95% CIs) associated with designated increases among lower values of certain baseline nutrition variables. Relative risks
shown by follow-up period: first 6 months (solid circles), 6 to 18 months (circles with crosses), and subsequently (squares).
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Results were adjusted for dose and flux treatment group, age, gender (except for
women's weight and Watson V, and arm circ. and mne's arm circ.), black race, diabetic
status, and dialysis duration.
Lower bound of 95% Cl for albumin relative risk in first 6 months = 0.37.
Fig. 10. Relative risks (and 95% CIs) associated with designated increases among higher values of certain baseline nutrition variables. Relative
risks shown by follow-up period: first 6 months (solid circles), 6 to 18 months (circles with crosses), and subsequently (squares).
Table 3. Multivariable models for relative risks of mortality associated with baseline nutrition factors for “short” and “long” follow-up periods in
the Hemodialysis (HEMO) Study population
Short follow-up (<6 months) Longer follow-up (≥6 months)
Variable Variable range Relative Risk (95% CI) P value Relative Risk (95% CI) P value
Serum albumin per 0.25 g/dL ≤3.635 g/dL 0.65 (0.53–0.79) <0.0001 0.84 (0.76–0.93) 0.0009
>3.635 g/dL 0.54 (0.31–0.94) 0.029 0.93 (0.31–0.94) 0.29
BMI per 1.0 kg/m2 ≤25 kg/m2 0.83 (0.77–0.91) <0.0001 0.94 (0.90–0.98) 0.0011
>25 kg/m2 1.02 (0.96–1.08) 0.53 0.99 (0.96–1.01) 0.30
enPCR per 0.25 g/kg/day ≤1.015 g/kg/d 0.92 (0.59–1.42) 0.70 0.94 (0.79–1.13) 0.53
>1.015 g/kg/d 1.10 (0.72–1.68) 0.66 1.10 (0.95–1.29) 0.22
t-chol per 10 mg/dL ≤168 mg/dL 0.94 (0.84–1.05) 0.26 0.96 (0.92–1.01) 0.094
>168 mg/dL 1.02 (0.93–1.11) 0.73 1.00 (0.97–1.03) 0.87
Serum creatinine per mg/dL all values 1.00 (0.91–1.10) 0.94 0.91 (0.87–0.94) <0.0001
All results adjusted for effects of HEMO dose and flux treatment assignment, age, sex, black race, presence of diabetes, and dialysis duration.
study was warranted. Many cohort studies have found
strong associations between a variety of nutritional in-
dices (typically laboratory parameters, due to ease of
collection) and mortality and morbidity in hemodialy-
sis patients [2–6, 22, 23]. The HEMO Study is unique
in that it evaluated numerous nutritional status indices
in a large population and over an extended follow-up
period. Most previous studies assumed that incremen-
tal risks were uniform across all parameter values and,
for the few studies that examined outcomes beyond a
year, that hazard remained constant. We hypothesized
that these assumptions might be violated. Indeed, the re-
lationships of most nutritional status indicators with mor-
tality in HEMO were nonlinear, and the predictive power
of baseline nutritional status diminished with length of
follow-up.
Our findings largely agree with those of Leavey
et al’s analysis of the United States Renal Data System
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(USRDS) data [24]. That study found that elevated serum
albumin and BMI values were independently associated
with decreased mortality, especially during early follow-
up. More recently, the international Dialysis Outcomes
and Practice Patterns Study (DOPPS), a prospective ob-
servational study of a random sample of 7710 hemodialy-
sis patients in 145 United States dialysis facilities, assessed
the risk of mortality for several baseline nutritional status
indicators, including BMI, serum albumin, serum creati-
nine, and nPCR while adjusting for age, race, sex, and 15
summary comorbid conditions [25]. DOPPS also found
higher mortality risk for lower baseline BMI, serum al-
bumin, and serum creatinine categories.
Our results confirm and extend these findings; thus,
hemodialysis patients with high levels of nutritional in-
dicators have reduced mortality compared to those with
low levels. However, most of the associations between the
nutritional indices and risk of mortality diminished over
longer periods of follow-up. From a biological standpoint
this is reasonable since all of these measures, including
weight, BMI, Watson V, and the anthropometric indices,
will change over a period of 6 months or more. Some,
such as enPCR, serum albumin, serum creatinine (in re-
sponse to diet), and t-chol, often do so in a matter of days
or weeks.
Several of the nutrition indicators exhibited inconsis-
tent attenuation trends, notably among lower levels of
t-chol and men’s MAC (Fig. 9) and among upper levels
of SS (Fig. 10). However, these inconsistencies were not
linked to the degree of instability for these measures, as
summarized by the volatility indices in Table 1.
Biochemical measures of nutritional status can reflect
early alterations in nutrient supplies to tissues, more ad-
vanced changes in tissue components, or other, often non-
specific alterations in metabolism. For example, enPCR
is an acute indicator of nutritional status that reflects re-
cent nitrogen intake and turnover over perhaps a week or
less. In this study, enPCR at baseline had relatively little
predictive power, perhaps because of week-to-week vari-
ability and thus, extensive misclassification. However, a
persistently low enPCR value might be more meaningful,
and this can be determined in longitudinal analyses of the
HEMO study data.
Serum creatinine reflects, in part, the status of lean tis-
sue and creatinine generation, and to a lesser extent, re-
cent dietary protein intake (meat and other foods high in
creatinine), thus serving as a nonspecific indicator of total
protein status [21]. Long-term changes in serum creati-
nine can mirror alterations in lean tissue mass but short-
term fluctuations are more likely to reflect alterations
in dietary intake. Chronically low levels suggest both de-
creased lean mass and probably decreased protein intake.
Acutely low levels suggest similar events but these would
be expected to be affected more by acute events (diet)
rather than chronic catabolism. Serum creatinine was a
good predictor of mortality in the HEMO Study, perhaps
indicating that somatic protein stores or lean tissue mass
are linked to mortality [26].
High levels of MAC and CC, which are indicative of
greater lean mass, were also associated with reduced mor-
tality. In overall analyses, there was little effect of ex-
cluding creatinine as a proxy for lean mass in explaining
associations of BMI with mortality over the entire range
of values. However, those who were overweight (BMI
>28 kg/m2), and who also had serum creatinine, arm cir-
cumferences, or calf circumferences above the median
were less likely to die over the course of follow-up than
those with values below the median, suggesting that a
high lean body mass afforded some protection. Moder-
ate overweight is associated with lower mortality [27].
BMI has a U-shaped relationship with all-cause mortal-
ity, whereas lean tissue mass has a monotonically inverse
relationship with mortality [28]. Thus, BMI in the HEMO
patients, as in healthy individuals, may mask the physio-
logically important underlying mechanisms linking body
composition with this and other disease, while lean tissue
mass has beneficial effects on longevity.
Serum albumin is another marker that is influenced by
protein and energy status and changes in hydration sta-
tus, but it is also an acute phase protein whose synthesis
is suppressed by inflammation [29, 30]. Therefore, the as-
sociation between serum albumin and mortality may be
magnified by its dual status as a marker of both malnu-
trition and disease (inflammation) even when hydration
status is constant [31, 32]. Also, with a half-life of 21 days,
serum albumin may be less sensitive to acute alterations
in protein and calorie intakes. Undernutrition increases
disease severity and synergistically affects other comor-
bidities, such as susceptibility to infections. Marked serum
albumin declines are frequently due to inflammation [32–
35]. Since an index of inflammation was only available
for patients enrolled for the later portion of the HEMO
Study, it was not possible to fully investigate its effects.
It is likely that the various causes of serum albumin de-
clines are associated with differences in mortality risk
[36]. However, there was very little change in RR with
serum albumin after adjusting for comorbid factors in
our analysis, suggesting that low serum albumin should
be a cause of concern for clinicians, both acutely as a
marker of the presence of inflammation or other events
that frequently impair nutrient intakes and may increase
requirements. If albumin is persistently low, chronic in-
take should be evaluated as well.
Cardiovascular and other chronic degenerative dis-
eases are more common causes of death in the hemodial-
ysis population than are infection or malnutrition [23].
Subjects with a high BMI were excluded from the HEMO
Study; nevertheless, there was no increased risk for
overweight patients with high BMI and SS levels. Subjects
with high BMI (25–31 kg/m2) tend to also have had large
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lean masses. Further investigation of corroborating data,
such as MAC and higher creatinines among them, would
be necessary to confirm this. Elevated t-chol was not as-
sociated with increased risk. This was expected since in-
creases among both lower and more moderate values of
t-chol were associated with decreased relative risk of mor-
tality among HEMO subjects.
A limitation to these analyses is that we used baseline
values for the nutritional status indicators so as to com-
pare our results with those of others. Time-dependent
analysis of repeated nutritional status parameters, es-
pecially those measured frequently, might have yielded
more accurate assessments of risk. Also, we simplified
our approach to the nonlinear models to avoid excessive
complexity, but by dichotomizing each two-slope vari-
able at the median and avoiding three-slope or other
more complex models, we may have excluded approaches
that could have explained more variability. The HEMO
Study inclusion and exclusion criteria and the intensity
with which subjects were monitored and supported may
also have varied from common clinical practice. The in-
terplay between nutritional status, therapy for perceived
undernutrition, comorbidity, and mortality might differ
considerably outside the clinical trial setting.
The RR reported here may misrepresent the true ef-
fects due to measurement error and contingency-related
interventions. The volatility indices in Table 1 showed that
several measures fluctuated more than others. If we had
used mean multiple baseline measures of the indices that
fluctuated the most, error might have been reduced and
more accurate protective effects may have been revealed.
Similarly, the Watson V was calculated using weight, and
prediction errors were introduced by using standard re-
gression coefficients [37].
Potential biases may have arisen because the HEMO
standards of care specified a review of the patient’s nutri-
tional status after marked reductions in serum albumin
or postdialysis weight (10% decline from baseline levels
for both or a drop of 2.5 kg in weight from baseline).
These reviews often triggered intensive dietary counsel-
ing and the prescription of oral nutritional supplements,
which may have skewed the results contributing to the
volatility of the data and perhaps may have mitigated pa-
tient mortality. To the extent that such interventions oc-
curred disproportionately among patients within narrow
and lower ranges of nutritional status values, the associ-
ations found in this study may have been biased.
CONCLUSION
Some anthropometric and laboratory parameters
of nutritional status are associated with mortality in
hemodialysis patients, but in a manner that is often non-
linear and time dependent. Studies aimed at improv-
ing, or at least maintaining, optimal nutritional status in
hemodialysis patients are warranted.
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